Rhythm Pharma Q3 net loss narrower than estimated on IMCIVREE demand

What happened

Rhythm Pharma's third-quarter net loss narrowed and beat analyst estimates, while product revenue rose 29% from the prior quarter on IMCIVREE demand. The company also secured a $750 mln term loan facility and amended its LG Chem licensing agreement.

Confirmed

Global impact / market context

A smaller loss plus rising IMCIVREE sales suggests product revenue is covering more of the company's costs. The $750 mln term loan, which means borrowed money, gives Rhythm cash to fund operations and the Japan launch without needing to raise equity soon.

Analyst inference

Analysts rate the stock a buy, reflecting optimism about IMCIVREE growth in acquired hypothalamic obesity and Bardet-Biedl syndrome. Management expects 2026 operating expenses of $360 mln to $380 mln, so revenue growth must keep pace as costs rise with global expansion.

Analyst inference

What to watch

1. Watch whether IMCIVREE patient demand keeps growing, since the company said sequential revenue growth came mainly from more patients in acquired hypothalamic obesity and Bardet-Biedl syndrome. Confirmed
2. Track the Japan commercial launch of IMCIVREE for acquired hypothalamic obesity, which management is pursuing to expand international reach and could add new revenue if adoption builds. Proposed
3. Compare 2026 revenue growth with planned operating expenses of $360 mln to $380 mln, because if sales lag, the narrowed loss could widen again and pressure the cash runway. Analyst inference

Evidence

• Original source link unavailable